You are here

  • Home
  • Archive
  • Volume 2018, Issue
  • Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
CASE REPORT
Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C
  1. Grace Elizabeth Dolman1,
  2. Paul Selby2,
  3. William T Gelson1
  1. 1 Department of Hepatology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  2. 2 Department of Pharmacy, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  1. Correspondence to Dr Grace Elizabeth Dolman, gracedolman1{at}nhs.net

Summary

The era of direct acting antivirals has revolutionised the management of chronic hepatitis C infection and improved patient outcomes. The optimal management of patients who require liver transplantation remains a matter of ongoing discussion. Treatment in the post-transplantation setting may be complicated by significant drug–drug interactions between antiviral agents and standard immune suppressive treatment regimens. We describe what we believe to be the first reported case of a patient successfully treated for CHC with ombitasvir/paritaprevir/ritonavir plus dasabuvir, while taking sirolimus following liver transplantation.

  • drug interactions
  • hepatitis C
  • drugs: infectious diseases
  • hepatitis and other Gi infections
  • transplantation

https://doi.org/10.1136/bcr-2018-224664

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors PS and WTG were involved directly in the management of clinical case described. Medical notes were summarised and the figure produced by GED. All the authors drafted and approved the case. All authors agreed to be accountable for the integrity of the case presented.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests WTG has given educational presentations for Abbvie and Gilead. He has also received meeting attendance grants from Abbvie and Gilead. He has provided consultancy work for Gilead. GED and PS have no financial disclosures.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.